Ignite Creation Date:
2024-10-26 @ 3:35 PM
Last Modification Date:
2024-10-26 @ 3:35 PM
Study NCT ID:
NCT06504966
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-07-10
Brief Title:
Study to Compare the Efficacy Pharmacokinetics Pharmacodynamics Safety and Immunogenicity of MAB-22 Versus Prolia
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Randomized Double-blind Parallel-group Active-controlled Study to Compare the Efficacy Pharmacokinetics Pharmacodynamics Safety and Immunogenicity of MAB-22 Versus Prolia Sourced From the European Union in Postmenopausal Women With Osteoporosis
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Double-blind Parallel-group Active-controlled Study to Compare the Efficacy Pharmacokinetics Pharmacodynamics Safety and Immunogenicity of MAB-22 Versus Prolia
Detailed Description:
A Randomized Double-blind Parallel-group Active-controlled Study to Compare the Efficacy Pharmacokinetics Pharmacodynamics Safety and Immunogenicity of MAB-22 Versus Prolia Sourced from the European Union in Postmenopausal Women with Osteoporosis
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None